The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 11, 2025
Filed:
Jan. 21, 2019
Applicants:
Baker Heart and Diabetes Institute, Melbourne, AU;
The Regents of the University of California, Oakland, CA (US);
The University of Sydney, Sydney, AU;
Inventors:
Anna Christine Drew, Cheltenham, AU;
Brian Gary Drew, Cheltenham, AU;
Thomas de Aguiar Vallim, Los Angeles, CA (US);
David James, Clontarf, AU;
Assignees:
Baker Heart and Diabetes Institute, Melbourne, AU;
The Regents of the University of California;
The University of Sydney, Sydney, AU;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/40 (2006.01); A61K 31/7115 (2006.01); A61K 31/712 (2006.01); A61K 31/7125 (2006.01); A61K 31/713 (2006.01); A61K 39/00 (2006.01); A61P 1/16 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 31/7115 (2013.01); A61K 31/712 (2013.01); A61K 31/7125 (2013.01); A61K 31/713 (2013.01); A61P 1/16 (2018.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01);
Abstract
The specification relates generally to the post-genomic identification of therapeutic targets and agents. In particular the specification relates to PSMD9 inhibitors and methods for preventing or treating metabolic disorders such as fatty liver disease that are associated with dysregulation of lipid homeostasis.